Long-term follow-up of patients with nonalcoholic fatty liver.

By Nila Rafiq, Chunhong Bai, Yun Fang, Manirath K. Srishord, A. McCullough, T. Gramlich, Z. Younossi. Clinical Gastroenterology and Hepatology, 2009

709 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Nutrition and Dietetics

View Paper: https://www.semanticscholar.org/paper/a240cb83e53e83f8475c4845d94b56d472b18da1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. M. Rinella
3. R. Loomba
4. S. Friedman
5. Gerald I. Shulman
6. K. Cusi
7. A. Sanyal
8. Megan H. Bair-Merritt

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. K. Cusi
4. A. Sanyal
5. S. Friedman
6. R. Loomba
7. E. Brunt
8. Gerald I. Shulman

In Nutrition and Dietetics

1. R. Gambino
2. G. Musso
3. M. Rinella
4. M. Cassader

Citations in the corpus

• Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality (2011, methodology): “patients on the NAFLD spectrum, only those with NASH are at risk for progression.(1,6-14) Because of this”
• Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity (2011, background): “While MR elastography is not broadly available, is expensive, and has not been internally or externally validated yet (17,20,54), ultrasonographic LSM by transient elastography (Fibroscan) is becoming increasingly used.”
• Association between Non-invasive Fibrosis Markers and Mortality among Adults with Non-alcoholic Fatty Liver Disease in the United States (2013, result): “Second, from this and other studies, it is clear that NAFLD without advanced fibrosis has little effect on mortality upon follow-up for up to two decades.(4,6,7,38) However, NAFLD with advanced fibrosis is an independent predictor of increased mortality, mainly from cardiovascular causes.”
• Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. (2009, background): “Nevertheless, the exact diagnosis is important since NASH is histologically progressive and can lead to cirrhosis whereas simple steatosis has a relatively benign course although it is not totally without histological consequences [148].”
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, background): “There is growing evidence that patients with histological NASH, especially those with some degree of fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality.((1,18,19,41-52)) These studies have also shown the following:”